Search Result

Results for "

clearance

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Amyloid-β (3) Apoptosis (2) Autophagy (5) Bacterial (4) BCRP (1) Beta-secretase (1) Biochemical Assay Reagents (2) c-Myc (1) Casein Kinase (1) CDK (1) CXCR (1) Endogenous Metabolite (2) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (1) GCGR (1) Glucosidase (2) HCV (1) Histone Methyltransferase (1) HIV (2) HIV Integrase (1) HSP (3) Influenza Virus (1) IRAK (5) LPL Receptor (1) mAChR (1) MMP (1) p38 MAPK (1) p62 (2) Parasite (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (3) PI3K (1) PI4K (1) Prostaglandin Receptor (1) Reactive Oxygen Species (1) SARS-CoV (1) Ser/Thr Protease (1) Sodium Channel (1) TNF Receptor (1) TRP Channel (1) Wnt (1) α-synuclein (1) γ-secretase (2)
By Research Areas:	Cancer (22) Cardiovascular Disease (6) Infection (13) Inflammation/Immunology (15) Metabolic Disease (15) Neurological Disease (13)

By Targets:

AMPK (1)

Amyloid-β (3)

Apoptosis (2)

Autophagy (5)

Bacterial (4)

BCRP (1)

Beta-secretase (1)

Biochemical Assay Reagents (2)

c-Myc (1)

Casein Kinase (1)

CDK (1)

CXCR (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (1)

Estrogen Receptor/ERR (1)

GCGR (1)

Glucosidase (2)

HCV (1)

Histone Methyltransferase (1)

HIV (2)

HIV Integrase (1)

HSP (3)

Influenza Virus (1)

IRAK (5)

LPL Receptor (1)

mAChR (1)

MMP (1)

p38 MAPK (1)

p62 (2)

Parasite (1)

PD-1/PD-L1 (1)

Phosphodiesterase (PDE) (3)

PI3K (1)

PI4K (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (1)

SARS-CoV (1)

Ser/Thr Protease (1)

Sodium Channel (1)

TNF Receptor (1)

TRP Channel (1)

Wnt (1)

α-synuclein (1)

γ-secretase (2)

By Research Areas:

Cancer (22)

Cardiovascular Disease (6)

Infection (13)

Inflammation/Immunology (15)

Metabolic Disease (15)

Neurological Disease (13)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12839

p38 MAPK-IN-1 Maximum Cited Publications 8 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC₅₀ of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.

HY-146111

IRAK4-IN-13	IRAK	Cancer
IRAK4-IN-13 (compound 21) is a potent and selective IRAK4 inhibitor with an IC₅₀ of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg .

HY-153241

GSK737	Epigenetic Reader Domain	Cancer
GSK737 is a BRD4 BD1 and BD2 inhibitor, with pIC₅₀ *values of 5.3 and 7.3 respectively. GSK737 has low clearance* and good solubility and permeability in rat .**

HY-W278021

BTA-1

Others Others

BTA-1 is an uncharged derivative of thioflavin-T. BTA-1 has high affinity for Aβ fibrils and shows very good brain entry and clearance .

BTA-1	Others	Others
BTA-1 is an uncharged derivative of thioflavin-T. BTA-1 has high affinity for Aβ fibrils and shows very good brain entry and clearance .

HY-143255

Enpp-1-IN-11	Phosphodiesterase (PDE)	Cancer
Enpp-1-IN-11 (compound 23) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an K_i value of 45 nM. Enpp-1-IN-11 exhibits low clearance in human and mouse liver microsomes, good plasma stability in human and mouse plasma. Enpp-1-IN-11 can be used for researching anticancer .

HY-139973

OAB-14	Amyloid-β	Neurological Disease
OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice .

HY-106443A

Arimoclomol maleate 2 Publications Verification BRX-220	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol maleate (BRX-220) is a co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .

HY-106443

Arimoclomol BRX-220 free base	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol (BRX-220 free base) is a co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .

HY-146113

IRAK4-IN-15	IRAK	Cancer
IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC₅₀ of 0.002 µM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. .

HY-106443B

Arimoclomol citrate BRX-220 citrate	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol citrate (BRX-220 citrate) is a co-inducer of heat shock proteins (HSP) . Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .

HY-B0372

Bromhexine	Others	Inflammation/Immunology
Bromhexine is a potent expectorant. Bromhexine increase mucociliary clearance and reduces cough. Bromhexine can be used in study various respiratory diseases .

HY-139875

JH-XVI-178

CDK Cancer

JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties.

JH-XVI-178	CDK	Cancer
JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties.

HY-N0901

Corynoxine	Autophagy	Neurological Disease Cancer
Corynoxine, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria rhynchophylla. Corynoxine is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

HY-N0901B

Corynoxine hydrochloride	Autophagy	Neurological Disease Cancer
Corynoxine hydrochloride, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria macrophylla. Corynoxine hydrochloride is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

HY-19947

PF-06291874 Glucagon receptor antagonists-4	GCGR	Metabolic Disease
PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .

HY-128060

PDE5-IN-42	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-42 (Compound 42) is a potent and orally active PDE5 inhibitor with an IC₅₀ of 0.04 nM. PDE5-IN-42 maintains selectivity over PDE6 and PDE11 .

HY-B0235

Trichlormethiazide	Others	Metabolic Disease
Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .

HY-B0235A

Trichlormethiazide sodium	Others	Metabolic Disease
Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .

HY-149345

IRAK4-IN-24	IRAK	Inflammation/Immunology
IRAK4-IN-24 (compound 16) is a potent IRAK4 inhibitor, with high clearance (Cl) and poor oral bioavailability. IRAK4-IN-24 can be used for research in inflammatory and autoimmune disorders.

HY-163040

DOTA-Tyr-Lys-DOTA	Others	Inflammation/Immunology
DOTA-Tyr-Lys-DOTA is a DOTA-based small molecule hapten. DOTA-Tyr-Lys-DOTAexhibits rapid clearance and low whole-body retention. DOTA-Tyr-Lys-DOTA can used in study pretargeted radioimmunotherapy .

HY-147263

Dovramilast CC-11050	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .

HY-120004

PF-06827443	mAChR	Infection
PF-06827443 is a potent, low-clearance, orally bioavailable, and CNS-penetrant M1-selective positive allosteric modulator (PAM) with minimal agonist activity. PF-06827443 induce cholinergic AEs and convulsion .

HY-120797

CRT0273750	LPL Receptor	Cancer
CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC₅₀ = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancer .

HY-112047

GSK8175 GSK2878175	HCV	Infection
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .

HY-W010382

Oxaloacetic acid 2-Oxosuccinic acid	Endogenous Metabolite Reactive Oxygen Species	Metabolic Disease
Oxaloacetic acid (2-Oxosuccinic acid) is a metabolic intermediate involved in several ways, such as citric acid cycle, gluconeogenesis, the urea cycle, the glyoxylate cycle, amino acid synthesis, and fatty acid synthesis, whereby Oxaloacetic acid facilitates the clearance of reactive oxygen species (ROS) and improves mitochondrial function .

HY-116494

ML753286	BCRP	Cancer
ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC₅₀ of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species .

HY-123494

BRD0418	Others	Cardiovascular Disease Neurological Disease
BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .

HY-N6904

Crocetin monomethyl ester	Amyloid-β	Neurological Disease Inflammation/Immunology
Crocetin monomethyl ester, isolated from Crocus sativus, possesses anti-inflammatory, neuroprotective and antioxidant activity . Crocetin monomethyl ester promotes clearance of amyloid-β by inducing autophagy via the STK11/LKB1-mediated AMPK pathway .

HY-108858

Dornase alfa rhDNase	Others	Others
Dornase alfa (rhDNase) is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. Dornase alfa plays an important role in cystic fibrosis .

HY-P5878

RG33 Peptide	Biochemical Assay Reagents	Metabolic Disease
RG33 Peptide is a diabetes inhibitor that significantly improves glucose clearance in insulin-resistant mice. RG33 Peptide effectively solubilizes lipid vesicles and promotes cholesterol efflux in cultured macrophages. RG33 Peptide is used in research into type 2 diabetes (T2D) .

HY-156188

AChE-IN-41	Others	Others
AChE-IN-41 (Compound 2) is a compound of the Galantamine Memantine hybrid. AChE-IN-41 has the inhibition ability of cholinesterase. AChE-IN-41 shows higher plasma stability and comparable microsomal stability in vitro, while showing lower half-life and faster clearance in vivo .

HY-111383

LX2343	Beta-secretase PI3K Amyloid-β Autophagy	Neurological Disease
LX2343 is a BACE1 enzyme inhibitor with an IC₅₀ value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC₅₀ of 15.99±3.23 μM. LX2343 stimulates autophagy in its promotion of Aβ clearance.

HY-B0235R

Trichlormethiazide (Standard)	Others	Metabolic Disease
Trichlormethiazide (Standard) is the analytical standard of Trichlormethiazide. This product is intended for research and analytical applications. Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .

HY-133869

cGMP-HTL cGMP-HaloTag-ligand	Autophagy	Cancer
cGMP-HTL contains a HT-ligand, a linker and the Cys-S-cGMP (autophagy tag). cGMP-HTL increases the K63-linked ubiquitination of mitochondria. AUTAC (autophagy-targeting chimera) is a novel targeted-clearance strategy that contains a degradation tag (guanine derivatives) and a warhead to provide target specificity .

HY-122958

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an inhibitor of α-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

HY-P2076

Dusquetide SGX942	p62 Bacterial	Infection Cancer
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection . DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

HY-113489

14,15-Epoxyeicosatrienoic acid 14,15-EET	Others	Cardiovascular Disease Neurological Disease
14,15-Epoxyeicosatrienoic acid (14,15-EET) is a metabolite of Arachidonic acid (HY-109590). 14,15-Epoxyeicosatrienoic acid is a potent inhibitor of in vivo platelet aggregation. 14,15-Epoxyeicosatrienoic acid facilitates astrocytic Aβ clearance. 14,15-Epoxyeicosatrienoic acid can be used for Alzheimer's Disease research .

HY-153256

EP3 antagonist 4	Prostaglandin Receptor	Metabolic Disease
EP3 antagonist 4 (Compound 28) is an EP3 antagonist, with a K_i value of 2 nM for hEP. EP3 antagonist 4 shows low in vivo clearance, high oral AUC, and good bioavailability in the rat full PK studies. EP3 antagonist 4 can be used for research of beta cell dysfunction in diabetes .

HY-155507

c-Myc inhibitor 11	c-Myc	Cancer
c-Myc inhibitor 11 (Compound 67e) is a c-MYC inhibitor (pEC₅₀: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research .

HY-P2076A

Dusquetide TFA SGX942 TFA	p62 Bacterial	Infection Cancer
Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection . DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

HY-P99052

Tislelizumab	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer .

HY-150502

Poly(styrenyl acetal trehalose) pSAT	Biochemical Assay Reagents	Others
Poly(styrenyl acetal trehalose) (pSAT) is composed of trehalose side chains linked to a polystyrene backbone via acetals. Poly(styrenyl acetal trehalose) stabilizes a variety of proteins and enzymes against fluctuations in temperature, and does not trigger the innate immune response. Poly(styrenyl acetal trehalose) can be used in synthesis of protein-polymer conjugates for reduced renal clearance of the biomolecule .

HY-P99552

Tafolecimab IBI-306	Ser/Thr Protease	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

HY-154823

Gcase activator 2	Glucosidase	Metabolic Disease
Gcase activator 2 (compound 14), a pyrrolo[2,3-b]pyrazine, is alos a β-Glucocerebrosidase (GCase) activator (EC₅₀=3.8 μM). Gcase activator 2 induces GCase dimerizatio (both K-type and V-type). And Gcase activator 2 has low metabolic clearance in human and mouse .

HY-143439

LX-039	Estrogen Receptor/ERR	Cancer
LX-039 is a highly potent, selective and orally active estrogen receptor degrader with EC₅₀ value of 2.29 nM. LX-039 has indole C-3 chlorine atom. LX-039 exhibits excellent mouse pharmacokinetics, low clearance, high C_max and oral exposure. LX-039 has anti-tumor activity .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-121845

4-Br-Bnlm	Others	Metabolic Disease
4-Br-Bnlm is a selective inhibitor of glucose-regulated protein 94 (Grp94) with an EC₅₀ value of 0.96 µM. 4-Br-Bnlm reduces the levels of mutant myocilin proteins as well as wild-type myocilin misfold in cells. 4-Br-Bnlm promotes the clearance of toxic formsof myocilin and reduces myocilin toxicity .

HY-116494A

(6R)-ML753286	Others	Cancer
(6R)-ML753286 is an isomer of ML753286 (HY-116494). ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC₅₀ of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species .

HY-150080

GSK3739936 BMS-986180	HIV HIV Integrase	Infection
GSK3739936 (BMS-986180) is a potent HIV-1 allosteric integrase inhibitor with an IC₅₀ value of 11.1 nM and an EC₅₀ value of 1.7 nM. GSK3739936 is also a weak CYP inhibitor (IC₅₀>24.3 μM). GSK3739936 shows favorable pharmacokinetic property in preclinical species with rapid absorption, low to moderate clearance and excellent oral bioavailability .

HY-12570

CK2-IN-9	Casein Kinase Wnt	Cancer
CK2-IN-9 is a potent and selective inhibitor of CK2 kinase with an IC₅₀ of 3 nM. CK2-IN-9 reduces Wnt reporter activity with an IC₅₀ of 75 nM. CK2-IN-9 has low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) properties in rat .

Cat. No.	Product Name

HY-L059

Pyroptosis Compound Library

1256 compounds

Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc.

MCE designs a unique collection of 1256 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signaling pathway and can be used in the research of pyroptosis signal pathway and related diseases.

HY-L174

Macrophage Related Compound Library

153 compounds

Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.

MCE designs a unique collection of 153 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Cat. No.	Product Name	Target	Research Area

HY-P99358

Dezamizumab GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)	Inhibitory Antibodies	Inflammation/Immunology
Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis .

HY-P99052

Tislelizumab	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P99340

Sotrovimab VIR 7831	SARS-CoV	Infection
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-P99552

Tafolecimab IBI-306	Ser/Thr Protease	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks